irusu
Posted - 17 hours ago
$FBIO FBIO DOWN 60% SINCE THE R/S INVESTORS LOST 93% OF THEIR SHARES 15-1 THIS GUY IS SUPPOSED TO BE A FINANCIAL EXPERT ???
CRAMER IS STILL WAITING FOR A RETURN PH CALL
braves1983
Posted - 22 hours ago
$FBIO another Fabolous day here at FBIO.....when is this stock going to fucking do anything??? its been months and months and here we are at $1.70.....
Radcon2017
Posted - 22 hours ago
$FBIO Price Channel has narrowed and is primed for a breakout…
Stock_Titan
Posted - 23 hours ago
$DERM $FBIO Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-present-at-the-planet-micro-cap-qbi6tl2soyrl.html
DameWave
Posted - 1 day ago
$FBIO James Oliviero is, so that everyone is on the record, a former employee Director of Finance for Rosenwald and Weiss who they themselves handpicked to be the CEO of $CKPT. He has no medical background! You can't fool anyone that the people who historically and today control decision making in $CKPT are Rosenwald and Weiss. Not only because they are the founders, that $FBIO owns 100% of the A shares, but that together with Wayne A. Marasco, M.D., Ph.D they sit on the knowledge. So now to my point, those who actually separate from SWICH do the homework casually blurt out that they don't want to own $CKPT because $FBIO controls the decisions. You should be very happy that $FBIO controls the decisions in $CKPT as they are the ones with the knowledge in this company.
DameWave
Posted - 1 day ago
$FBIO $CKPT history part 4 With this deal, the aim was to develop a portfolio of fully human immuno-oncology targeted antibodies. In the acquisition, they also secured the wisdom of the discoverer of these antibodies in the form of Dr. Wayne Marasco, MD, PhD, a Professor in the Department of Cancer Immunology and AIDS at Dana-Farber Cancer Institute (Dana-Farber), who was given the role of Chairman of the Checkpoint Scientific Advisory Board (a position he still holds today). As Rosenwald was the CEO of Fortress Biotech and Weiss of TG Therapuetics $TGTX (which was now taking off), Weiss and Rosenwald hired their former associate James Oliviera as President & Chief Executive Officer of Checkpoint Therapuetics. Weiss took on the role of Chairman of the Board of Directors while Rosenwald also took a seat on the board.
DameWave
Posted - 1 day ago
$FBIO $CKPT history part 3 The acquisition and the early collaborations that started it all In 2014 Rosenwald paired up with Weiss again, and in the same year, they founded Checkpoint Therapeutics. This as they saw great potential in checkpoint inhibitor therapy, a form of cancer immunotherapy. In March 2015, Coronado Biosciences (Fortress Biotech today after the name change) then bought licenses rights to 3 novel immuno-oncology targeted antibodies, including Anti-PD-L1, Anti-GITR and Anti-CAIX from Dana-Farber. In a founders and management services agreement with Fortress and Checkpoint (these can be read on p. 57 of Checkpoint's annual report 2022, Exhibit No. 10.1-10.4), effective March 17, 2015 (which was amended in July 2016 and October 2017) assumed $2.8 million in debt that Fortress accumulated under a promissory note through National Securities Corporation for expenses and costs of forming Checkpoint.
DameWave
Posted - 1 day ago
$FBIO $CKPT history part 2: One who was highly involved in the hiring of Weiss and the acquisition of Access Oncology was Lindsay Rosenwald, the founder of Fortress Biotech, who was on the board of directors for Keryx Biopharmaceuticals between 2002 and 2006, before he resigned in order to devote more direct time to the biotechnology market. One person who stayed longer was James Oliviero who was Director of Finance for ACCESS Oncology under Weiss, and after the acquisition he was given the title of Chief Financial Officer at Keryx Biopharmaceuticals. Oliviero stayed until 2015 after Keryx received FDA approval for Auryxia in 2014 and EMA marketing approval in 2015. https://checkpointtx.com/about/
DameWave
Posted - 1 day ago
$FBIO Of course, Checkpoint may be acquired or merged in the future, but the ones who control this are Checkpoint's founders, Fortress Biotech. Is this not relevant to describe when addressing only $CKPT with your posts? And is it so strange that Fortress owns this right? Feels like a little history is in order. $CKPT history part 1 Founders Michael Weiss, TG Therapeutics & Fortress Biotech, founded Access Oncology which was acquired by Keryx Biopharmaceuticals in 2004. What stands out a bit is that since 2002 Weiss had also been Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, so it can almost be defined as a merger. Weiss led Keryx to acquire and develop its lead drug Auryxia, which would later receive FDA approval. Weiss stayed with Keryx until 2009.
DameWave
Posted - 1 day ago
$CKPT Sorry, but, I can't stay away from this "gut" talk anymore, and him continuing to ignore $FBIO part. What is official information according to the latest FY 2023 report is that Checkpoint themselves write 5 times that: "The Company is a majority-controlled subsidiary of Fortress Biotech, Inc. ("Fortress")." And that Fortess Biotech: "... , of which 700,000 shares have been designated as Class A common stock." "All of the Class A common stock has been issued to Fortress." (Exhibit 4.6) And not a word about Checkpoint currently being indebted to Fortress (image). Why describe both sides of the coin when you only need to describe the one that benefits you? For full transparency, I own shares in both $FBIO and $CKPT
braves1983
Posted - 1 day ago
$FBIO still hasnt done anything in months. still cant stay above $1.80. no news. no results on anything. where is the direction here? no one knows anything and that is why it sits at $1.70
Scientwist
Posted - 2 days ago
$FBIO $ATXI Avenue's reverse split creates a low float stock, cutting shares from 42M to 0.6M. Expect high volatility—rapid price changes offering both risk and reward. Stay sharp. #StockMarket #Investing
Freedom1992
Posted - 2 days ago
$FBIO FBIO can buy out Avenue.
Xenovestor
Posted - 3 days ago
$FBIO been watching this one since 2020. Looking to start a long position soon. Keep it low ✌🏽
AnUnwiseInvestor
Posted - 3 days ago
$AQST Still waiting for 23.53 to sell. Got in long before the big run and sold my principal to buy into $FBIO and $AUR for two possible more big runs later on this year. This is how you gamble. It’s outrageous I know.
Freedom1992
Posted - 5 days ago
$FBIO don't just focus on a buyout of DERM. Cyprium is a likely hot target for Sentynl.
DameWave
Posted - 5 days ago
@StockednLoaded Shut down X also after low interest. Thanks, but I'm done with these types of forums. People spend more time asking a question or making a claim than it would actually take to find the answer themselves. Will continue to be super long $FBIO
DameWave
Posted - 6 days ago
$FBIO Wrote this (picture) earlier today but now see that ST did not want to let it through to be seen (no fuss due to criticism). If you are interested, send a follow request.
Good luck to every long here. Bye!
DameWave
Posted - 6 days ago
$FBIO If I take your money, wouldn't you want it back? $DERM Do you seriously mean if you hypothetically were the CEO of Galderma and had the cash to buy DFD-29 for $420 M to get a much better product, and also avoid competing with this superior product, than the one you just last year sold for $300 M you would pass? Don't you understand that Oracea will be faced with a generic of their own product and DFD-29 in the sales fight? (The rest of you don't need to worry, there's no way DERM is releasing DFD-29 that cheap)
DameWave
Posted - 6 days ago
@omega42 "It would be foolish to spend another $400M+ to acquire and market competing product when they already have that market covered." Dumbest thing I've ever heard. If you have a product that sells for about $300 M per year 2 decades after it was approved... Was it worth spending $420 M on the buy? Again, Oracea has been sold for billions if you add up all the years... Now if there is a competing product (DFD-29) that has been shown in comparative studies to be totally clinically superior (again, I have never seen such a statistically superior medical product when you compare it to a standard of care product), and which is also "the first and only systemic therapy indicated for both inflammatory lesions and erythema in rosacea"... Then don't you want to own that product? $FBIO $DERM
DameWave
Posted - 6 days ago
$FBIO If you read the data and read the points on these two pictures, do you understand now @omega42 why Galderma would want to own DFD-29? $DERM
DameWave
Posted - 6 days ago
$FBIO Market covered? Yes, and that is EXACTLY WHAT THEY ARE AFRAID OF LOSING! $DERM Can't you read? Don't know what happens when you co-compete with generics over your own product? And when you need to compete against a new product that has proven to be almost TWICE as good (DFD-29)? Read and review "DFD-29 CLINICAL OVERVIEW"-presentation in the link. If you don't understand after that, I can't help you... https://ir.journeymedicalcorp.com/company/presentations $XBI
DameWave
Posted - 6 days ago
$FBIO Are you kidding with me? If you can't bear to do the homework yourself, read all my posts on $DERM from April... Galderma bought Oracea in 2008 for $420 million (unbelievably cheap!) and it is still the standard of care. Sold for billions until now, when their patent expired and they lost the battle against generics (Lupin) this month. Galderma was so paranoid about losing market share in 2021-2022 in rosacea in the US that they entered into a sales agreement with a product they knew was significantly worse than their own (EPSOLAY, from SLGL), and they also knew that it had failed FDA inspections plan due to Covid -19 problems. DFD-29 is the SUPERIOR Oracea (read my old posts). Do you think they will just lie flat about losing one of their best selling products of the last two decades when they have a market cap of over 15 billion against a competitor that has a $69 M market cap? $XBI
omega42
Posted - 6 days ago
$FBIO Have not do DD on Galderma but what do they already have approved in the market space where DFD29 plans to compete? If nothing than i would agree for Galderma to acquire $DERM but if there is already something being offered that is approved and marketed, that would be waste on their part.
DameWave
Posted - 6 days ago
$FBIO $CKPT $TGTX NO! "Effective September 30, 2023, the Company and TGTX agreed to mutually terminate these collaborations, with full rights reverting back to us" Want more proof? Checkpoint writes it clearly and repeatedly, time and time again, on page 2, 3, 4, 5, 10, 12, 43, 50, F-11, F-16, F-17, Exhibit 10.12.2, Exhibit 10.12.3. https://ir.checkpointtx.com/financial-information/financial-results https://content.equisolve.net/checkpointtx/sec/0001410578-24-000283/for_pdf/ckpt-20231231xex10d122.htm https://content.equisolve.net/checkpointtx/sec/0001410578-24-000283/for_pdf/ckpt-20231231xex10d123.htm "As a holder of both"... Do your homework then!
DameWave
Posted - 6 days ago
$FBIO DERM is down -21% (sick) this week, yet FBIOs 53% in DERM is valued $37 M... The entire FBIOs portfolio is valued at...(*drum roll*)... $33 M (insane)! What is it that the market does not understand? $XBI
DameWave
Posted - 6 days ago
$FBIO And they have already succeeded within the $FBIO (if one of the two Phase 3 reaches all the way, more money than what they have had so far will start pouring in): "Last year, Fortress' partner company Caelum Biosciences entered a $500 million agreement with Alexion Pharmaceuticals for CAEL-101, a first-in-class monoclonal antibody to treat light chain (AL) amyloidosis. We're excited to see that drug candidate move towards the market.” https://pharmaphorum.com/views-analysis-market-access/qa-fortress-biotech-on-breathing-new-life-into-sidelined-drugs $XBI
DameWave
Posted - 6 days ago
$FBIO Again, this text about $MBIO is a must read!
DameWave
Posted - 6 days ago
$FBIO “I think a lot of our findings are reshaping the field and how we’re thinking about applying cell therapy to brain tumors,” $MBIO
